NewAmsterdam Pharma Company N.V.
Support and Resistance Levels
Past performance
News About NAMS
All events for NAMS
All deals for NAMS
Financial Ratios
Financial Statements
NAMS vs Sector & Peers
About NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands. Website newamsterdampharma.com
Headquarters Naarden, NH, NL